课题基金 / 基金详情

Defining Early Stages of Polyomavirus CNS Pathogenesis and Immunity

Defining Early Stages of Polyomavirus CNS Pathogenesis and Immunity
定义多瘤病毒中枢神经系统发病机制和免疫的早期阶段
批准号:
10365345
负责人:
Aron Eliot Lukacher
金额:
$43.09万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-05-01 至 2023-01-31
关键词:
Acquired Immunodeficiency SyndromeAdultAnimal ModelAnti-Inflammatory AgentsAntibody RepertoireAntibody ResponseAutoimmuneAutoimmunityB-Lymphocyte EpitopesBiologicalBiological ProductsBloodBrainBrain DiseasesCD8-Positive T-LymphocytesCapsid ProteinsCellsCentral Nervous System DiseasesCentral Nervous System InfectionsCentral Nervous System Viral DiseasesCerebrumChoroid Plexus EpitheliumClinicalClinical TrialsComplicationCryoelectron MicroscopyCustomDemyelinationsDepressed moodDevelopmentDiagnosisDiseaseEngineeringEpendymaEpitopesEventFamilyFoundationsGrantHematologic NeoplasmsHumanImmuneImmune EvasionImmunityImmunocompromised HostImmunoglobulin GImmunologicsImmunomodulatorsImmunosuppressionImmunotherapeutic agentIncidenceIndividualInfectionInflammatoryIntegrin alpha4JC VirusKidneyLeadLesionLifeLinkMapsMediatingModelingMolecularMonoclonal AntibodiesMorbidity - disease rateMusMutant Strains MiceMutationNatural ImmunityNeurotropismParentsPathogenesisPatientsPlasma ExchangePolyomavirusPolyomavirus InfectionsPopulationProcessProgressive Multifocal LeukoencephalopathyReactionRelapseReportingResistanceResolutionRiskSTAT1 geneSeriesSiteStagingStretchingSystemic Lupus ErythematosusT-LymphocyteTestingTherapeuticThree-Dimensional ImagingTropismTysabriUrinary tractUrineValidationVariantVentricularViralViral PathogenesisViremiaVirusVirus Diseasesbrain parenchymachemotherapeutic agentclinical practicedrug candidatedrug withdrawalhuman pathogenhuman viromeimage reconstructionimprovedin vivoin vivo evaluationmacrogliamortalitymouse polyomavirusmultiple sclerosis patientmutantnatalizumabneuropathologyneutralizing antibodynext generation sequencingpathogenpre-clinicalpreservationresponsesmall moleculesubventricular zonetissue culture

项目摘要

项目成果

Aron Eliot Lukacher的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 JC多瘤病毒(JCPyV)是一种普遍存在的人类病原体,在中国引起几种毁灭性的脑部疾病 免疫受损的个体。这些与JCPyV相关的中枢神经系统疾病中最值得注意的是 常常是致命的脱髓鞘脑病,进行性多灶性白质脑病(PML)。PML,一个 在CART之前的时代,艾滋病定义的病变已经成为威胁患者生命的并发症 自身免疫性和炎症性疾病的免疫调节剂和某些疾病的治疗 恶性血液病。在迅速扩大的与PML相关的生物制品清单中,Natalizumab (Tysabri®)发病率最高,对于以下多发性硬化症(MS)患者来说是不祥的后遗症 否则将受益于使用这种免疫调节剂大幅减少复发。戒毒, PML的唯一治疗选择往往是高死亡率的脑炎性反应。不是 有抗JCPyV的试剂可用。缺乏易处理的多瘤病毒引起的中枢神经系统疾病的动物模型是一种 阐明PML发病机制的公认瓶颈,控制JCPyV的时间免疫学机制,在 组织培养中抑制多瘤病毒复制的药物的体内评估,并揭示早期事件 预示着不可逆的JCPyV相关神经病理--这一更新应用的重点。使用鼠标 多瘤病毒(MuPyV),我们建立了多瘤病毒相关中枢神经系统疾病的自然病毒宿主模型。在……里面 在本次续订申请中,我们将利用母公司R01授权下的两个主要发现:(1)地图 JCPyV-PML VP1衣壳蛋白突变到MuPyV的VP1使人能够逃避病毒中和抗体 (2)依赖STAT1的先天免疫限制感染 室管膜,随后脑实质感染的关键屏障。这两个发现都有相似之处 JCPyV的这些问题,为本续签申请中提出的两个关键问题奠定了基础:(1)是 室管膜是多瘤病毒侵袭脑实质的分期场所吗?以及(2)T细胞 缺乏为NAB逃逸病毒变种的产生打开了大门?拟议的研究将利用 新一代测序技术的尖端进展,可在体内发现罕见的VP1突变,定制冷冻EM 图像重建方法,以确定内源性VP1 NAB表位和NAB逃逸机制,以及 对小鼠大脑进行高分辨率3D成像,以可视化病毒中枢神经系统的进入和传播。来自这些的发现 研究将回答有关JCPyV的先天性和获得性免疫控制的基本问题,并可能 改进JCPyV相关中枢神经系统疾病高危患者的识别标准。
英文摘要
ABSTRACT JC polyomavirus (JCPyV), a ubiquitous human pathogen, causes several devastating brain diseases in immune compromised individuals. The most notable of these JCPyV-associated CNS diseases is the frequently fatal demyelinating brain disease progressive multifocal leukoencephalopathy (PML). PML, an AIDS-defining lesion in the pre-cART epoch, has emerged as a life-threatening complication in patients receiving immunomodulatory agents for autoimmune and inflammatory disorders and treatment for certain hematological malignancies. Among the rapidly expanding list of PML-associated biologics, natalizumab (Tysabri®) has the highest incidence and is an ominous sequela for multiple sclerosis (MS) patients who otherwise benefit from dramatic reductions in relapses using this immunomodulatory agent. Drug withdrawal, the only therapeutic option for PML, is often complicated by a high-mortality cerebral inflammatory reaction. No anti-JCPyV agents are available. Lack of a tractable animal model of polyomavirus-induced CNS disease is an acknowledged bottleneck to elucidating PML pathogenesis, timmunological mechanisms that control JCPyV, in vivo evaluation of agents that inhibit polyomavirus replication in tissue culture, and uncovering early events that presage irreversible JCPyV-associated neuropathology – the focus of this renewal application. Using mouse polyomavirus (MuPyV), we developed a natural virus-host model of polyomavirus-associated CNS disease. In this renewal application, we will leverage two key findings made under the parent R01 grant: (1) Mapping JCPyV-PML VP1 capsid protein mutations to MuPyV’s VP1 confers escape from virus-neutralizing antibodies (nAb) while preserving CNS tropism; and (2) STAT1-dependent innate immunity limits infection of the ventricular ependyma, a critical barrier to subsequent brain parenchymal infection. Both findings, which parallel those of JCPyV, lay the foundation for the two key questions raised in this renewal application: (1) Is the ependyma the staging ground for polyomavirus invasion of the brain parenchyma?; and (2) Does T cell deficiency open the door for outgrowth of nAb-escape virus variants? The proposed studies will make use of cutting edge advances in next-generation sequencing to uncover rare VP1 mutations in vivo, custom cryo EM image reconstruction approaches to define endogenous VP1 nAb epitopes and nAb escape mechanisms, and high-resolution 3D imaging of mouse brains to visualize viral CNS entry and spread. Findings from these studies will answer fundamental questions about innate and adaptive immune control of JCPyV and potentially improve criteria for identifying patients at risk for JCPyV-associated CNS diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Deciphering Early Stages of Polyomavirus CNS Pathogenesis and Immunity
Deciphering Early Stages of Polyomavirus CNS Pathogenesis and Immunity
Deciphering Early Stages of Polyomavirus CNS Pathogenesis and Immunity
Pathogenesis of Mouse Polyomavirus-associated CNS Demyelination
海外基金